Entelos Presents Webinar Comparing Human and Rodent Type 2 Diabetes Physiology on Thursday, June 28, 2012
Making assumptions about the similarity of outcomes between laboratory species and humans is often disappointing after much investment of time and cost. Entelos’ ability to explain these phenomena through mechanism-based predictions is revolutionizing a fundamental translational research challenge.
San Mateo, CA (PRWEB) June 19, 2012
Metabolism PhysioLab® Used to Compare Rodent to Human Data and Predict How and Why They Differ
Entelos, a premier provider of in silico modeling and simulation products and consulting services, will be hosting a live webinar presenting Dr. Xiao Wang’s work using the Metabolism PhysioLab platform, explaining the mechanistic difference between rodents and humans when attempting to target a particular enzyme of interest to treat Type 2 diabetes. Making assumptions about the similarity of outcomes between laboratory species and humans is often disappointing after much investment of time and cost. Entelos’ ability to explain these phenomena through mechanism-based predictions is revolutionizing a fundamental translational research challenge. Webinar registration at: https://cc.callinfo.com/r/155hy0mc1bm71
“Our Metabolism Physiolab platform has been built focusing on the fundamental physiological pathways affected by diabetes” stated Entelos’ President and CEO, Shawn O’Connor. “We are developing powerful insights about the differences between species that enlighten how and when researchers should consider rats and mice appropriate animal models to study diabetes – resulting in great economies.”
In this webinar, Dr. Xiao Wang will introduce the “top-down” in silico modeling approach utilized in the Entelos Metabolism PhysioLab platform and its applications in predicting clinical outcomes of diabetes treatments and translational medicine. Particularly, a case study recently featured in the ADA’s 72nd Scientific Poster Session “Inter-Species differences contributing to poor translatability of sustained glucose lowering effects of glycogen phosphorylase inhibition from rodent to human” will be used as a case study in which simulation results were used to streamline therapeutic target validation and improve the rate of successful translation from pre-clinical studies to the clinic. A copy of the poster may be viewed at http://www.entelos.com/resources/.
Entelos has fully developed platforms in multiple disease areas in addition to Metabolism (with diabetes and obesity) including: Cardiovascular Disease, Rheumatoid Arthritis, Hypertension (with heart and kidney failure), Dermatology, Hematology, Infection, Nutrition, and Veterinary Nutrition.
Entelos is an in silico modeling and simulation software and services company delivering predictive technologies reducing risk, time, and cost of product development for pharmaceutical, biotechnology, nutrition and consumer products customers. The Company’s PhysioLab systems biology platforms generate virtual patient populations providing highly predictive analyses to develop safer and more effective drugs, foods and consumer products. Entelos’ understanding of patient variability has significant application to the emerging field of personalized medicine. The Company is headquartered in San Mateo, California. For more information, please visit http://www.entelos.com.
Wendy Shelton, 650-572-5430
VP, Corporate Communications
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebmetabolism/therapeutics/prweb9616795.htm